Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib and Docetaxel Neoadjuvant in HER2+ Breast Cancer
NCT00450892Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2007
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of lapatinib in breast cancer (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Maximum Tolerated Dose, Pathological Complete Response Rate and 1 more. Started Feb 2007; status: completed.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00450892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00450892.